Redeye strengthens its positive view of ADDvise following a Q3 report beating our forecasts on sales...
Intellego meddelade under gårdagen den 27 oktober 2022 att det licensavtal som bolaget tecknade i ma...
ARR of SEK 67.4m, up 15% y-o-y, -3% vs. ABGSCe Committed to cash flow break-even Share trading at ’2...
Consumables slump signalling bigger slowdown We cut ‘23e EBIT by 4% on lower growth and margins Trad...
Poor Q3 margins on lower delivery sales in Public DK We cut ‘22e-‘24e EBIT by 13-8% Opex growth to s...
Q3 adj. EBIT of SEK 62m, 24% above ABGSC AUM growth of 5% q-o-q, will drive positive revisions Earni...
Sales +5%, EBIT +12% vs. ABGSC, 34% organic sales Solid end to 2022, some cautious remarks on 2023 2...
Redeye sees a couple of bright spots in the Q3 report, such as a new record level for sales of Parts...
Delving into the Q3 results, we note adj. EBIT grew 41% YOY (in line with our forecast), lending cre...
Solteq’s Q3 was somewhat below our expectations and most notably, challenges were seen now also in S...
Finnair’s Q3 results came in clearly above estimates as strong development in unit revenues drove to...
Consti reported Q3 figures that were in line with our estimates.
Verkkokauppa.com’s Q3 result came in soft as expected.
CapMan continued its good performance in Q3 and results apart from carried interest corresponded to ...
Redeye endorses aXichem’s new patent for phenylcapsaicin for use in the treatment of idiopathic pulm...
Redeye takes a more positive stance towards Addnode following an excellent Q3 report, driven by stro...
Redeye reiterates its SEK 132 base case for BONESUPPORT following the Q3 report.
Redeye comments on Sleep Cycle's Q3 report, which showed higher profitability than expected, while t...
Redeye states that the Q3 report was better than expected on EBITDA and in line with net sales estim...
Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report.
